OFFER 15% cbd flower
EL CBD PODRÍA PREVENIR EL COVID

CBD MAY PREVENT COVID IN EARLY STAGES

Preclinical experiments in human cells and mice suggest that cannabidiol, a primary active compound in hemp and marijuana (Cannabis sativa), can prevent SARS-CoV-2 replication in the early stages of infection, shortly after the virus has entered cells. The study, published January 20, 2022 in the journal 'Science Advances,' found that CBD showed a significant negative association with positive SARS-CoV-2 tests in a nationwide sample of medical records of patients taking the FDA-approved drug to treat epilepsy.

 

However, clinical trials must now be conducted to determine whether CBD could eventually be used as a preventive or early treatment against the coronavirus.

 

CBD to treat seizures

 

In addition, a correlative analysis of 1212 patients who had a history of using cannabidiol (CBD) to treat seizures showed a substantially lower rate of SARS-CoV-2 infection compared to matched control groups. This is currently the only FDA-approved use for CBD.

Emphasizing the importance of not self-inferring this substance, Long Chi Nguyen and his team advocate for rigorous clinical trials to evaluate the potential of CBD as a therapeutic intervention for Covid-19, including its potential effects throughout the course of SARS-CoV-2 infection. According to the scientists, the results provide "a strong rationale for doing so."

 

The researchers detail that they only observed antiviral activity in CBD and its metabolite 7-OH-CBD and did not see similar results in several closely related cannabinoid compounds, such as cannabidilic acid, cannabidivarin, cannabichromene, and cannabigerol.

In addition, they also found that tetrahydrocannabinol (THC), the main psychoactive compound in C. sativa grown for marijuana use, could strongly counteract the antiviral effects of CBD that they observed . The authors state that this finding "essentially eliminates the feasibility of marijuana serving as an effective source of antiviral CBD."

 

 

The researchers treated human lung cancer cells expressing the ACE2 receptor, the key entry point for SARS-CoV-2, with CBD two hours before infection with the virus. After 48 hours, the team observed strong inhibition of viral replication, with no observable toxic effects.

 

The researchers repeated these experiments with two other types of human cells and three variants of the virus (Alpha, Beta and Gamma), all with comparable results.Noting that some previously investigated therapies for SARS-CoV-2 showed promise in cell-based experiments but did not work well in live animal tests, Nguyen and his team also tested their results in mice expressing the human ACE2 receptor.

 

They injected mice with CBD twice daily at two different doses for a week before SARS-CoV-2 infection and continued for four days after infection. At both the lower and higher doses, CBD reduced viral load and none of the mice lost weight or showed signs of clinical disease. "These results establish the preclinical efficacy - tissues and animal models - of CBD as an antiviral drug for SARS-CoV-2 during the early stages of infection," the authors of the paper conclude.

 

RELATED PRODUCTS:

https://www.efectocbd.es/efectocbdstore/efectocbd/departments

 

EL CBD PODRÍA PREVENIR EL COVID
  • 1108   
EFECTO HEMP SL | CIF: B09664848 | REUS - TARRAGONA (SPAIN)
0
Close
0 Articles
Subtotal 0,00 €
Email
Contact us